<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcophthalmol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Ophthalmology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcophthalmol/</link>
        <description>The latest research articles published by BMC Ophthalmology</description>
        <dc:date>2012-05-30T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/11" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/10" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/9" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/8" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/7" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/5" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2415/12/2" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/11">
        <title>Hospitalized cardiovascular events in patients with diabetic macular edema</title>
        <description>Background:
Microvascular and macrovascular complications in diabetes stem from chronic hyperglycemia and are thought to have overlapping pathophysiology.  The aim of this study was to investigate the incidence rate of hospitalized myocardial infarctions (MI) and cerebrovascular accidents (CVA) in patients with diabetic macular edema (DME) compared with diabetic patients without retinal diseases.
Methods:
This was a retrospective cohort study of a commercially insured population in an administrative claims database. DME subjects (n = 3519) and diabetes controls without retinal disease (n = 10557) were matched by age and gender. Healthcare claims were analyzed for the study period from 1 January 2002 to 31 December 2005. Incidence and adjusted rate ratios of hospitalized MI and CVA events were then calculated.
Results:
The adjusted rate ratio for MI was 2.50 (95% CI: 1.83-3.41, p &lt; 0.001) for DME versus diabetes controls. Predictors of MI events were heart disease, history of acute MI, and prior use of antiplatelet or anticoagulant drugs. The adjusted rate ratio for CVA was 1.98 (95% CI: 1.39-2.83, p &lt; 0.001) for DME versus diabetes controls. Predictors of CVA events were cardiac arrhythmia, Charlson comorbidity scores, history of CVA, hyperlipidemia, and other cerebrovascular diseases.
Conclusion:
Event rates of MI or CVA were higher in patients with DME than in diabetes controls. This study is one of few with sufficient sample size to accurately estimate the relationship between DME and cardiovascular outcomes.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/11</link>
                <dc:creator>Bao-Anh Nguyen-Khoa</dc:creator>
                <dc:creator>Earl Goehring</dc:creator>
                <dc:creator>Winifred Werther</dc:creator>
                <dc:creator>Anne Fung</dc:creator>
                <dc:creator>Diana Do</dc:creator>
                <dc:creator>Rajendra Apte</dc:creator>
                <dc:creator>Judith Jones</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:11</dc:source>
        <dc:date>2012-05-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-11</dc:identifier>
                                <prism:require>/content/figures/1471-2415-12-11-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2012-05-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/10">
        <title>An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent</title>
        <description>Background:
Vascular endothelial growth factor (VEGF) plays an important role in ocular physiology. Anti-VEGF agents are now used for treatment of common retinal diseases. This study characterises the vasoactive properties of VEGF in isolated perfused pig retinal arterioles under normal tone or endothelin-1 (ET-1) pre-contracted conditions and determines the influence of an anti VEGF agent on VEGF induced vasoactivity.
Methods:
An isolated perfused retinal arteriole preparation was used.  The outer diameter of retinal vessels was monitored at 2 second intervals in response to VEGF and the anti VEGF agent, bevacizumab.  The effect of intraluminal delivery of VEGF was determined over a wide concentration range (10-16 to 10-7 M) both with and without pre-contraction with ET-1 (3 x 10-9 M).  Bevacizumab (0.35 mg mL-1) was applied extraluminally to determine the influence of bevacizumab on VEGF induced vasoactive changes on ET-1 pre-contracted vessels.
Results:
In retinal arterioles with normal tone, VEGF induced a concentration dependent contraction at low concentrations, reaching 93.5% at 10-11 M and then contraction was reduced at higher concentrations, recovering to 98.1% at 10-7 M.  VEGF produced a potent concentration dependent vasodilatation in arterioles pre-contracted with ET-1.  VEGF induced vasodilatation in arterioles pre-contracted with ET-1 was significantly inhibited by bevacizumab.
Conclusions:
VEGF induced vasoactive changes in pig retinal arterioles are dependent on concentration and vascular tone.  Bevacizumab inhibits VEGF-induced vasodilatation in pre-contracted arterioles.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/10</link>
                <dc:creator>Er-Ning Su</dc:creator>
                <dc:creator>Stephen Cringle</dc:creator>
                <dc:creator>Ian McAllister</dc:creator>
                <dc:creator>Dao-Yi Yu</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:10</dc:source>
        <dc:date>2012-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-10</dc:identifier>
                                <prism:require>/content/figures/1471-2415-12-10-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2012-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/9">
        <title>A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 micro g/mL to latanoprost 50 micro g/mL (Xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension</title>
        <description>Background:
Several studies have investigated the effect of latanoprost on intraocular pressure (IOP). We compared the IOP-lowering effects of three higher concentrations of latanoprost with the commercially available concentration of 0.005% (50 micro g/mL) in patients with primary open-angle glaucoma or ocular hypertension.
Methods:
Treatment-naive subjects or those receiving IOP-lowering medication with baseline IOP levels of &#191;24 mmHg and &#191;36 mmHg in at least one eye after washout were randomized to receive an evening dose of latanoprost 50, 75, 100, or 125 &#191;g/mL for 4 weeks. At weeks 1, 2, 3, and 4, ocular examinations were performed and IOP was measured. Ocular symptoms and adverse events were monitored. The primary efficacy endpoint was the change in IOP from baseline to week 4 at 8 a.m. and 4 p.m. for the per protocol (PP) population using a &quot;worse eye&quot; analysis. Secondary efficacy endpoints were change in IOP at each time point from baseline across all visits, and percentage change in IOP from baseline to week 4 at 8 a.m.
Results:
In all, 282 patients were randomized and treated; 274 were included in the PP population. Treatment groups were similar at baseline; 68% were diagnosed with primary open-angle glaucoma. Mean baseline IOP levels were comparable across treatments. There were no statistically significant differences in IOP reductions from baseline to week 4 at either time point between those treated with higher concentrations of latanoprost versus those receiving 50 &#191;g/mL. Least squares mean IOP changes at 8 a.m. were &#191;10.13, -9.59, -10.02, and &#191;9.06 mmHg for latanoprost 50, 75, 100, and 125 &#191;g/mL, respectively, and at 4 p.m. were &#191;8.90, -8.29, -8.81, and &#191;8.34 mmHg, respectively. Results of secondary efficacy analyses supported those of the primary analysis. Conjunctival hyperemia, the most commonly reported adverse event, occurred in 16.9%, 18.6%, 20.8% and 15.9% of subjects receiving latanoprost 50, 75, 100, and 125 &#191;g/mL, respectively.
Conclusions:
IOP reductions were observed in all treatment groups postbaseline, with no clinically relevant or statistically significant differences detected favoring any of the higher concentrations of latanoprost compared with latanoprost 50 micro g/mL. All doses of latanoprost were well tolerated. Clinical Trials.gov Identifier NCT01379144.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/9</link>
                <dc:creator>David Eveleth</dc:creator>
                <dc:creator>Charles Tressler</dc:creator>
                <dc:creator>Carla Starita</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:9</dc:source>
        <dc:date>2012-05-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-9</dc:identifier>
                            <dc:title>Dose effect of latanaprost</dc:title>
                            <dc:description>The safety and efficacy of three higher concentrations of latanaprost was not significantly different when compared with the standard commercially available dose in a large prospective parallel group study.</dc:description>
                <prism:require>/content/figures/1471-2415-12-9-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2012-05-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/8">
        <title>Retro-mode imaging and fundus autofluorescence with
scanning laser ophthalmoscope of retinal dystrophies</title>
        <description>Background:
Retinal dystrophies display a considerably wide range of phenotypic variability, which can make diagnosis and clinical staging difficult. The aim of the study is to analyze the contribution of retro-mode imaging (RMI) and fundus autofluorescence (FAF) to the characterization of retinal dystrophies.
Methods:
Eighteen consecutive patients affected by retinal dystrophies underwent a complete ophthalmological examination, including best corrected visual acuity with ETDRS charts, blue-light fundus autofluorescence, (BL-FAF), near-infrared fundus autofluorescence (NIR-FAF), and RMI. The primary outcome was the identification of abnormal patterns on RMI. The secondary outcome was the correlation with the findings on BL-FAF and NIR-FAF.
Results:
Overall, the main feature of RMI is represented by a pseudo-3D pattern of all the lesions at the posterior pole. More specifically, any accumulation of material within the retina appears as an area of elevation of different shape and size, displaying irregular and darker borders. No precise correlations between RMI, BL-AF, and NIR-AF imaging was found.
Conclusions:
RMI and FAF appear to be useful tools for characterizing retinal dystrophies. Non-invasive diagnostic tools may yield additional information on the clinical setting and the monitoring of the patients.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/8</link>
                <dc:creator>Battaglia Parodi Maurizio</dc:creator>
                <dc:creator>Iacono Pierluigi</dc:creator>
                <dc:creator>Kontadakis Stelios</dc:creator>
                <dc:creator>Vergallo Stefano</dc:creator>
                <dc:creator>Cascavilla Marialucia</dc:creator>
                <dc:creator>Zucchiatti Ilaria</dc:creator>
                <dc:creator>Bandello Francesco</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:8</dc:source>
        <dc:date>2012-05-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-8</dc:identifier>
                                <prism:require>/content/figures/1471-2415-12-8-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2012-05-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/7">
        <title>European ST80 community-associated methicillin-resistant Staphylococcus aureus orbital cellulitis in a neonate</title>
        <description>Background:
Methicillin-resistant Staphylococcus aureus is a serious cause of morbidity and mortality in hospital environment, but also, lately, in the community. This case report is, to our knowledge, the first detailed description of a community-associated methicillin-resistant S. aureus ST80 orbital cellulitis in a previously healthy neonate. Possible predisposing factors of microbial acquisition and treatment selection are also discussed.Case presentationA 28-day-old Caucasian boy was referred to our hospital with the diagnosis of right orbital cellulitis. His symptoms included right eye proptosis, periocular edema and redness. Empirical therapy of intravenous daptomycin, rifampin and ceftriaxone was initiated. The culture of pus yielded a methicillin-resistant S. aureus isolate and the molecular analysis revealed that it was a Panton-Valentine leukocidine-positive ST80 strain. The combination antimicrobial therapy was continued for 42 days and the infection was successfully controlled.
Conclusions:
Clinicians should be aware that young infants, even without any predisposing condition, are susceptible to orbital cellulitis caused by community-associated methicillin-resistant S. aureus. Prompt initiation of the appropriate empirical therapy, according to the local epidemiology, should successfully address the infection, preventing ocular and systemic complications.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/7</link>
                <dc:creator>Evangelia Tsironi</dc:creator>
                <dc:creator>Fani Zacharaki</dc:creator>
                <dc:creator>Ioanna Grivea</dc:creator>
                <dc:creator>Sofia Tachmitzi</dc:creator>
                <dc:creator>Aspasia Michoula</dc:creator>
                <dc:creator>Marianna Vlychou</dc:creator>
                <dc:creator>Efthimia Petinaki</dc:creator>
                <dc:creator>George Syrogiannopoulos</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:7</dc:source>
        <dc:date>2012-04-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-7</dc:identifier>
                                <prism:require>/content/figures/1471-2415-12-7-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2012-04-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/6">
        <title>Heightened expression of MICA enhances the cytotoxicity of NK cells or CD8+T cells to human corneal epithelium in vitro</title>
        <description>Background:
Major-histocompatibility-complex class I-related chain A (MICA) antigens are the ligands of NKG2D which is an activating or coactivating receptor expressed on human NK cells and CD8+ T cells. We sought to determine whether MICA expression in human corneal epithelium (HCE) could affect the cytotoxicity mediated by NK cells or CD8+ T cells.
Methods:
Cell cultures of HCE were harvested from human donor eyes. Flow cytometric analysis and ELISA was performed to determine the levels of MICA expression on HCE. Then, HCE was transfected with lentivirus vector expressing MICA and GFP. Flow cytometric analysis, RT-PCR, Western blot and ELISA was performed to check the levels of MICA expression. For cytotoxicity testing, allogeneic NK cells and CD8+ T cells were isolated from peripheral blood mononuclear cells of healthy voluteers by magnetic cell sorting. The cytolytic activity of NK cells and CD8+ T cells was assessed against MICA-transfected HCE (NK cells: E:T ratio=3:1; CD8+T cells: E:T ratio=10:1) using the nonradioactive cytotoxicity detection kit lactate deshydrogenase.
Results:
Surface expression of MICA on corneal epithelium was identified at low level. A cell line of stable human MICA-transfected corneal epithelium was successfully established. Heightened expression of MICA on HCE was found to promote the cytotoxicity mediated by NK cells or CD8+T cells, which could be blocked by anti-MICA antibody.
Conclusion:
MICA molecule may contribute to cytotoxic responses mediated by activated immune effector cells in corneal epithelium immunity.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/6</link>
                <dc:creator>Jiaxu Hong</dc:creator>
                <dc:creator>Ting Qiu</dc:creator>
                <dc:creator>Tingting Qian</dc:creator>
                <dc:creator>Gang Li</dc:creator>
                <dc:creator>Xiaobo Yu</dc:creator>
                <dc:creator>Junyi Chen</dc:creator>
                <dc:creator>Qihua Le</dc:creator>
                <dc:creator>Xinghuai Sun</dc:creator>
                <dc:creator>Jianjiang Xu</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:6</dc:source>
        <dc:date>2012-04-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-6</dc:identifier>
                                <prism:require>/content/figures/1471-2415-12-6-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2012-04-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/5">
        <title>Eye care utilization by older adults in low, middle, and high income countries</title>
        <description>Background:
The risk of visual impairment increases dramatically with age and therefore older adults should have their eyes examined at least every 1 to 2 years. Using a world-wide, population-based dataset, we sought to determine the frequency that older people had their eyes examined . We also examined factors associated with having a recent eye exam.
Methods:
The World Health Surveys were conducted in 70 countries throughout the world in 2002-2003 using a random, multi-stage, stratified, cluster sampling design. Participants 60 years and older from 52 countries (n = 35,839) were asked &quot;When was the last time you had your eyes examined by a medical professional?&quot;. The income status of countries was estimated using gross national income per capita data from 2003 from the World Bank website. Prevalence estimates were adjusted to account for the complex sample design.
Results:
Overall, only 18% (95% CI 17, 19) of older adults had an eye exam in the last year. The rate of an eye exam in the last year in low, lower middle, upper middle, and high income countries was 10%, 24%, 22%, and 37% respectively. Factors associated with having an eye exam in the last year included older age, female gender, more education, urban residence, greater wealth, worse self-reported health, having diabetes, and wearing glasses or contact lenses (p &lt; 0.05).
Conclusions:
Given that older adults often suffer from age-related but treatable conditions, they should be seen on a regular basis to prevent visual impairment and its disabling consequences.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/5</link>
                <dc:creator>Claudia Vela</dc:creator>
                <dc:creator>Elodie Samson</dc:creator>
                <dc:creator>Maria Victoria Zunzunegui</dc:creator>
                <dc:creator>Slim Haddad</dc:creator>
                <dc:creator>Marie-Josee Aubin</dc:creator>
                <dc:creator>Ellen Freeman</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:5</dc:source>
        <dc:date>2012-04-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-5</dc:identifier>
                                <prism:require>/content/figures/1471-2415-12-5-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2012-04-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/4">
        <title>Intrinsically photosensitive retinal ganglion cell function in relation to age
A pupillometric study in humans with special reference to the age-related optic properties of the lens
</title>
        <description>Background:
The activity of melanopsin containing intrinsically photosensitive ganglion retinal cells (ipRGC) can be assessed by a means of pupil responses to bright blue (appr.480 nm) light. Due to age related factors in the eye, particularly, structural changes of the lens, less light reaches retina. The aim of this study was to examine how age and in vivo measured lens transmission of blue light might affect pupil light responses, in particular, mediated by the ipRGC.
Methods:
Consensual pupil responses were explored in 44 healthy subjects aged between 26 and 68 years. A pupil response was recorded to a continuous 20 s light stimulus of 660 nm (red) or 470 nm (blue) both at 300 cd/m2 intensity (14.9 and 14.8 log photons/cm2/s, respectively). Additional recordings were performed using four 470 nm stimulus intensities of 3, 30, 100 and 300 cd/m2.The baseline pupil size was measured in darkness and results were adjusted for the baseline pupil and gender. The main outcome parameters were maximal and sustained pupil contraction amplitudes and the postillumination response assessed as area under the curve (AUC) over two time-windows: early (0-10 s after light termination) and late (10-30 s after light termination). Lens transmission was measured with an ocular fluorometer.
Results:
The sustained pupil contraction and the early poststimulus AUC correlated positively with age (p=0.02, p=0.0014, respectively) for the blue light stimulus condition only.The maximal pupil contraction amplitude did not correlate to age either for bright blue or red light stimulus conditions.Lens transmission decreased linearly with age (p&lt;0.0001). The pupil response was stable or increased with decreasing transmission, though only significantly for the early poststimulus AUC to 300 cd/m2 light (p=0.02).
Conclusions:
Age did not reduce, but rather enhance pupil responses mediated by ipRGC. The age related decrease of blue light transmission led to similar results, however, the effect of age was greater on these pupil responses than that of the lens transmission. Thus there must be other age related factors such as lens scatter and/or adaptive processes influencing the ipRGC mediated pupil response enhancement observed with advancing age.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/4</link>
                <dc:creator>Kristina Herbst</dc:creator>
                <dc:creator>Birgit Sander</dc:creator>
                <dc:creator>Henrik Lund-Andersen</dc:creator>
                <dc:creator>Adam Elias Broendsted</dc:creator>
                <dc:creator>Line Kessel</dc:creator>
                <dc:creator>Michael Stormly Hansen</dc:creator>
                <dc:creator>Aki Kawasaki</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:4</dc:source>
        <dc:date>2012-04-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-4</dc:identifier>
                            <dc:title>Age enhances retinal ganglion cell function</dc:title>
                            <dc:description>Activity of intrinsically photosensitive retinal ganglion cells in healthy patients, assessed by pupil responses to bright blue light (480 nm), correlates positively with age.</dc:description>
                <prism:require>/content/figures/1471-2415-12-4-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-04-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/3">
        <title>Fibrin membrane pupillary-block glaucoma after uneventful cataract surgery treated with intracameral tissue plasminogen activator: a case report</title>
        <description>Background:
Fibrin pupillary-block glaucoma is a rare complication after cataract surgery. The treatment for this condition is still controversial, since Nd:YAG laser fibrin membranotomy tends to reocclude and laser peripheral iridotomy entails the risk of damaging the corneal endothelium in the presence of corneal edema associated with elevated intraocular pressure.Case presentationA 62-year-old man with diabetes mellitus developed acute elevation of intraocular pressure with a shallow anterior chamber five days after uneventful cataract surgery. Initially, slit lamp examination provided only limited information due to severe corneal edema. After resolution of corneal edema with systemic glaucoma therapy, a complete fibrin membrane was observed across the pupil by slit lamp examination. Anterior segment optic coherence tomography clearly revealed a thin fibrin membrane covering the entire pupillary space, a shallow anterior chamber, and a deep posterior chamber. The intraocular lens was not observed by anterior segment optic coherence tomography. In contrast, ultrasound biomicroscopy, which has superior penetration depth, was able to visualize the intraocular lens deep in the posterior chamber. Injection of tissue plasminogen activator into the anterior chamber resulted in complete fibrinolysis and released the pupillary block.
Conclusion:
This case suggests that ocular anterior segment imaging modalities, especially ultrasound biomicroscopy, serve as powerful diagnostic tools to identify mechanisms of acute angle closure glaucoma, which is often accompanied by poor intraocular visibility. This is the first reported case of fibrin pupillary-block glaucoma after cataract surgery successfully treated with intracameral tissue plasminogen activator.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/3</link>
                <dc:creator>Hideaki Yoshino</dc:creator>
                <dc:creator>Masaaki Seki</dc:creator>
                <dc:creator>Jun Ueda</dc:creator>
                <dc:creator>Takaiko Yoshino</dc:creator>
                <dc:creator>Takeo Fukuchi</dc:creator>
                <dc:creator>Haruki Abe</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:3</dc:source>
        <dc:date>2012-03-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-3</dc:identifier>
                                <prism:require>/content/figures/1471-2415-12-3-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-03-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2415/12/2">
        <title>Results at seven years after the use of Intracamerular cefazolin as an endophthalmitis prophylaxis in cataract surgery</title>
        <description>Background:
To evaluate results after seven years using prophylactic intracameral cefazolin for the prevention of endophthalmitis in cataract surgery.
Methods:
A prospective, observational study of all patients submitted to cataract surgery over the period January 1996 to December 2009. All cases of postoperative endophthalmitis over that period were reviewed. The patients were classified in two groups: Group 1 (11,696 patients) operated on between January 1996 and December 2002, Group 2 (13,305 patients) between January 2003 and December 2009 (in whom a 1 mg/0.1 bolus of intracameral cefazolin was instilled).
Results:
During the study period, 76 cases of endophthalmitis were observed in Group 1, and seven in Group 2. The rate of postoperative endophthalmitis reduced from 0.63% to 0.05% with a cefazolin injection. The relative risk (RR) for endophthalmitis in Group 1 against group 2 was 11.45 [95% CI 5.72-22.84, p &lt; 0.001].
Conclusions:
An intracameral bolus injection of cefazolin (1 mg in 0.1 ml solution) at the conclusion of the cataract surgery significantly reduced the rate of postoperative endophthalmitis.</description>
        <link>http://www.biomedcentral.com/1471-2415/12/2</link>
                <dc:creator>Pedro Romero-Aroca</dc:creator>
                <dc:creator>Isabel Mendez-Marin</dc:creator>
                <dc:creator>Merce Salvat-Serra</dc:creator>
                <dc:creator>Juan Fernandez-Ballart</dc:creator>
                <dc:creator>Matias Almena-Garcia</dc:creator>
                <dc:creator>Javier Reyes-Torres</dc:creator>
                <dc:source>BMC Ophthalmology 2012, null:2</dc:source>
        <dc:date>2012-01-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2415-12-2</dc:identifier>
                            <dc:title>Reducing postoperative endophthalmitis</dc:title>
                            <dc:description>Patients undergoing cataract surgery are less likely to develop postoperative endophthalmitis if given an intracameral injection of cefazolin at the end of surgery, compared to patients not given intracameral cefazolin.</dc:description>
                <prism:require>/content/figures/1471-2415-12-2-toc.gif</prism:require>
                <prism:publicationName>BMC Ophthalmology</prism:publicationName>
        <prism:issn>1471-2415</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-01-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

